Matches in Wikidata for { <http://www.wikidata.org/entity/Q59400313> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q59400313 description "article scientifique publié en 2014" @default.
- Q59400313 description "article" @default.
- Q59400313 description "im Jahr 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59400313 description "wetenschappelijk artikel" @default.
- Q59400313 description "наукова стаття, опублікована у 2014" @default.
- Q59400313 name "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 name "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 type Item @default.
- Q59400313 label "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 label "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 prefLabel "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 prefLabel "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 P1433 Q59400313-E3585D33-9B92-4564-9FD3-40E05580E09A @default.
- Q59400313 P1476 Q59400313-A03D2E70-00DF-45C5-AD25-666E6459A9D3 @default.
- Q59400313 P2093 Q59400313-0D0767E3-F121-4285-8415-12993424893F @default.
- Q59400313 P2093 Q59400313-1813FF5B-674B-46BB-BE44-C67A7EECFE47 @default.
- Q59400313 P2093 Q59400313-2946609F-A8C7-4110-8BB6-70CAACDF7537 @default.
- Q59400313 P2093 Q59400313-2AE9290F-BB4F-46C1-B463-CD2053656231 @default.
- Q59400313 P2093 Q59400313-37927D67-42C5-4F7C-BF5A-7C54A24D35D8 @default.
- Q59400313 P2093 Q59400313-430361E7-10F5-46E4-9884-A05796B574DD @default.
- Q59400313 P2093 Q59400313-541D2315-7EC7-4AAC-A808-F7102C4947E6 @default.
- Q59400313 P2093 Q59400313-7362DDA6-DCB5-4997-A3D2-AB98C43D7939 @default.
- Q59400313 P2093 Q59400313-7ECA94E0-793E-4D5B-A418-41E517E328B0 @default.
- Q59400313 P2093 Q59400313-9E5F3158-568B-4879-B5D0-D586628BCF70 @default.
- Q59400313 P2093 Q59400313-A5DBC7C9-0AA9-4C7C-8812-B27017BF32C8 @default.
- Q59400313 P2093 Q59400313-AAC6178F-4180-4E94-8EE2-F809E92340E4 @default.
- Q59400313 P2093 Q59400313-BAAE046C-2749-410D-B843-B33B367E2FA1 @default.
- Q59400313 P2093 Q59400313-CABBCF29-A382-499B-B32D-83D99E47BB94 @default.
- Q59400313 P2093 Q59400313-D8A97F8D-F6FF-4DAC-8C70-5850CEFA83FC @default.
- Q59400313 P2888 Q59400313-333A5F4C-0DB4-4C28-B969-C3DB8013A87E @default.
- Q59400313 P304 Q59400313-E9985EB0-98D5-485C-84ED-22EE76FA968D @default.
- Q59400313 P31 Q59400313-3FD3739E-F939-4BD5-8F5A-0FB6E332BC72 @default.
- Q59400313 P356 Q59400313-25AD1800-71DB-4B18-B524-466B3C03448C @default.
- Q59400313 P433 Q59400313-048D7C36-C350-4C25-95A4-A30294C538A3 @default.
- Q59400313 P478 Q59400313-C4BE4155-8103-4A1B-8E7C-4081146616AD @default.
- Q59400313 P50 Q59400313-867EA73C-73B6-4E66-AE0E-A6F57696495C @default.
- Q59400313 P577 Q59400313-65204031-AF42-461C-98D0-9798C1DAC292 @default.
- Q59400313 P6179 Q59400313-A8270671-A717-420D-BC1B-18ED08F9D0C4 @default.
- Q59400313 P921 Q59400313-60F0D17B-1BA2-4910-9C1D-FABE57C4F2CA @default.
- Q59400313 P932 Q59400313-93C08BA9-6507-4DAF-B9CA-847574DDD5D1 @default.
- Q59400313 P356 2051-1426-2-S3-P263 @default.
- Q59400313 P1433 Q27725163 @default.
- Q59400313 P1476 "Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)" @default.
- Q59400313 P2093 "Ai Li" @default.
- Q59400313 P2093 "Frances A Collichio" @default.
- Q59400313 P2093 "Howard Kaufman" @default.
- Q59400313 P2093 "Jason Chesney" @default.
- Q59400313 P2093 "Keith Delman" @default.
- Q59400313 P2093 "Kevin Harrington" @default.
- Q59400313 P2093 "Lynn Spitler" @default.
- Q59400313 P2093 "Mark Middleton" @default.
- Q59400313 P2093 "Mark Shilkrut" @default.
- Q59400313 P2093 "Mohammed Milhem" @default.
- Q59400313 P2093 "Neil Senzer" @default.
- Q59400313 P2093 "Robert Coffin" @default.
- Q59400313 P2093 "Robert HI Andtbacka" @default.
- Q59400313 P2093 "Sanjiv Agarwala" @default.
- Q59400313 P2093 "Thomas Amatruda" @default.
- Q59400313 P2888 2051-1426-2-s3-p263 @default.
- Q59400313 P304 "P263-P263" @default.
- Q59400313 P31 Q13442814 @default.
- Q59400313 P356 "10.1186/2051-1426-2-S3-P263" @default.
- Q59400313 P433 "Suppl 3" @default.
- Q59400313 P478 "2" @default.
- Q59400313 P50 Q66829274 @default.
- Q59400313 P577 "2014-01-01T00:00:00Z" @default.
- Q59400313 P6179 "1042181601" @default.
- Q59400313 P921 Q42824827 @default.
- Q59400313 P932 "4292568" @default.